Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation - Normandie Université Access content directly
Journal Articles Thyroid Year : 2017

Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation

Abstract

Medullary thyroid carcinomas (MTCs) complicated by ectopic Cushing's syndrome (CS) have a poor prognosis, partially due to the difficulty in controlling hypercortisolism by adrenal blocking drugs. Recent reports (including the initial follow-up of this patient) have suggested that tyrosine kinase inhibitors (TKIs) may be a therapeutic option due to an anti-secretory action on ACTH. However, there is a lack of long-term follow-up studies.
No file

Dates and versions

hal-01945860 , version 1 (05-12-2018)

Identifiers

Cite

Estelle Louiset. Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation. Thyroid, 2017, 27 (4), pp.587-590. ⟨10.1089/thy.2016.0334⟩. ⟨hal-01945860⟩
28 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More